Repligen

Last updated
Repligen Corporation
Company type Public
Nasdaq:  RGEN
S&P 400 Component
IndustryPharmaceutical industry
Founded1981;43 years ago (1981)
FoundersAlexander Rich
Paul Schimmel
Headquarters
Waltham, Massachusetts
,
United States
Key people
Tony J. Hunt (president and CEO)
ProductsMaterials used in the manufacture of biological drugs
RevenueIncrease2.svgUS$68 million (2014)
Increase2.svgUS$23 million (2014)
Total assets Increase2.svgUS$119 million (2014)
Total equity Increase2.svgUS$104 million (2014)
Number of employees
116 (2014)
Website repligen.com

Repligen Corporation is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and was incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2] In February 2014, Repligen had employed 116 people, about 50% of these based in Sweden. [3]

Contents

Business model

Before 2012, Repligen maintained dual capabilities in developing pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business). [4] A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures. [5] In the period of 2010 to 2013, the majority of sales by the company were concentrated in the single Protein A product line. [6]

Sales and revenue

Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets". [7] More than 80% of sales have been to customers in the United States and Sweden during the 2010-2013 period. [7] Long-term supply agreements have been established with major customers of the Protein A products, agreements which expire between 2016 and 2021 barring re-negotiation. [8]

As a result of royalty-generating out-licensing, royalty revenue from Bristol-Myers Squibb has been in the 27% to 37% range as a proportion of total revenue during the 2010-2013 period; in comparison to revenue from sales, the largest customer accounted for 35% to 45% of revenue during the same period. [3]

As a consequence of current operations, about one-third each of revenue and cost and expenses are denominated in Swedish krona currency, the remaining two-thirds denominated in United States dollars; this presents a risk to the business based on unpredictable fluctuations in currency exchange rates. [9]

Intellectual property

The company's Protein A-related offerings are supported by proprietary technology, trade secrets and patent filings. [3] One patent was granted in April 2010 and has been extended so that it remains in effect until 2028. [3] [10] Patents are pending on elements of the OPUS chromatography product line, [3] and enabling technology has been licensed from BioFlash Partners. [6] Repligen retains an exclusive license to intellectual property owned by the University of Michigan in relation to the Orencia product divested to Bristol-Myers Squibb. [7] [11]

Facilities

Repligen's company headquarters are housed together with its manufacturing facility in Waltham, Massachusetts. [12]

Repligen maintains manufacturing facilities in Waltham, Massachusetts and Lund, Sweden. [1] Growth factor products and the native form of Protein A are manufactured in Sweden; recombinant forms of Protein A are manufactured in both the United States and Sweden; assembly of the OPUS chromatography product line is done in the United States. [8]

The lease on the main Waltham facility extends through 2023. [12] A second, smaller Waltham facility was leased through the end of 2012 and is now rented on a monthly basis. [13] In Lund, four buildings are under lease, three expiring in mid-2017 and the fourth extending to late 2019. [13]

Corporate history and governance

Alexander Rich was a co-founder of Repligen and served as Chairman Emeritus [14] of Repligen's board of directors. Rich had been a member of the Board since 1981. [15] Paul Schimmel is also a co-founder of Repligen, and he is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He used to be the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.

As of 2015, the company's President and Chief Executive Officer is Tony J. Hunt.

Acquisitions and in-licensing

In early 2010, Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre-packed chromatography columns. [6]

In 2011, Repligen acquired bioproduction assets from Novozymes for $26.4 million, which doubled the company's bioprocessing capabilities. [4]

In December 2016 the company acquired TangenX for $39 million [16]

In September 2023, Repligen acquired a fluid management company, Metenova. [17]

Divestments and out-licensing

In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013. [4]

At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer. [4] This divestment included licensing rights to two patents to Pfizer. [8] [18] [19]

At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$ 2,000,000 and future milestone and royalty payments. [1] [20]

Terminations and moth-balling

Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application (NDA) submission; a Marketing Authorization Application had been submitted in parallel to the EMA. [1]

Products and services

Repligen is a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry. [4] In 2010-2013, Protein A accounted for the majority of the company's product sales. [6] The company also provides growth factors to increase the productivity of cell-based bioproduction, multiple alternating tangential flow (ATF) systems, and a line (OPUS) of chromatography columns scaled to manufacture of product for testing in clinical trials. [4]

The OPUS product line contains a range of column sizes, the size and composition of which are dependent upon customer requirements, thus the full name of "Open Platform, User Specified". [5] The smaller sizes of columns depend upon proprietary technology licensed from BioFlash Partners, while the larger sizes are based on Repligen-developed proprietary technology. [6]

Notes

  1. 1 2 3 4 Repligen 2013 10-K 2014, p. 2.
  2. ↑ Nasdaq :  RGEN
  3. 1 2 3 4 5 Repligen 2013 10-K 2014, p. 6.
  4. 1 2 3 4 5 6 Repligen 2013 10-K 2014, p. 1.
  5. 1 2 Repligen 2013 10-K 2014, p. 4.
  6. 1 2 3 4 5 Repligen 2013 10-K 2014, p. 3.
  7. 1 2 3 Repligen 2013 10-K 2014, p. 5.
  8. 1 2 3 Repligen 2013 10-K 2014, p. 7.
  9. ↑ Repligen 2013 10-K 2014, p. 18.
  10. ↑ B2 US 7691608 B2 "Nucleic Acids Encoding Recombinant Protein A"
  11. ↑ US 6685941 "Methods of treating autoimmune disease via CTLA-4Ig"
  12. 1 2 Repligen 2013 10-K 2014, p. 19.
  13. 1 2 Repligen 2013 10-K 2014, p. 20.
  14. ↑ Motley Fool 2014.
  15. ↑ Forbes 2014.
  16. ↑ "Repligen Acquires TangenX for $39M". 15 December 2016.
  17. ↑ "Repligen (RGEN) to Acquire Fluid Management Company Metenova". Nasdaq.com . September 27, 2023.
  18. ↑ US 7888366 "2,4-diaminoquinazolines for spinal muscular atrophy"
  19. ↑ US 7985755 "2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY"
  20. ↑ Gen. Eng. Biotechnol. News 2014.

Related Research Articles

Opus is a Latin word meaning "(a result of) work". Italian equivalents are opera (singular) and opere (plural).

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming.

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.

Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group.

Cangene Corporation was a biopharmaceutical company based in Winnipeg, Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. Cangene was 61% owned by Canadian pharmaceutical giant Apotex and was publicly listed on the TSX under the symbol CNJ.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

This page provides an alphabetical list of articles and other pages about biotechnology.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller III to describe an imaginative and risk-taking approach to philanthropy that may be undertaken by charitable organizations.

Fed-batch culture is, in the broadest sense, defined as an operational technique in biotechnological processes where one or more nutrients (substrates) are fed (supplied) to the bioreactor during cultivation and in which the product(s) remain in the bioreactor until the end of the run. An alternative description of the method is that of a culture in which "a base medium supports initial cell culture and a feed medium is added to prevent nutrient depletion". It is also a type of semi-batch culture. In some cases, all the nutrients are fed into the bioreactor. The advantage of the fed-batch culture is that one can control concentration of fed-substrate in the culture liquid at arbitrarily desired levels.

Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company was headquartered in Redwood City, CA. It dissolved in 2013. The Maxygen legacy was revived in 2018 with a focus on Directed Evolution of Proteins using Molecular Breeding. Maxygen LLC is currently headquartered in Sunnyvale, CA.

Applied Biosystems is one of various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them.

Merck Millipore was the brand used by Merck Group's global life science business until 2015 when the company re-branded. It was formed when Merck acquired the Millipore Corporation in 2010. Merck is a supplier to the life science industry. The Millipore Corporation was founded in 1954, and listed among the S&P 500 since the early 1990s, as an international biosciences company which makes micrometer pore-size filters and tests. In 2015, Merck acquired Sigma-Aldrich and merged it with Merck Millipore. In the United States and Canada, the life science business is now known as MilliporeSigma.

<span class="mw-page-title-main">Sartorius AG</span> German pharmaceutical company

Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services.

Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.

<span class="mw-page-title-main">Protalix BioTherapeutics</span> Israeli pharmaceutical company

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

Bioproduction is the production of biologics-based therapeutic drugs including protein-based therapeutics, vaccines, gene therapies as well as cell therapies; drugs so complex they can only be made in living systems or indeed are a living system. In practice, ‘bioproduction’ has become loosely synonymous with ‘bioprocessing’ as a way to describe the manufacturing process using, cell culture, chromatography, formulation and related analytical testing for large molecule drugs, vaccines and cellular therapies. Many combinations of reactor types and culture modes are now available for use in bioproduction: e.g., pharming, rocking wave-agitated bag batch, stirred-tank or air-lift fed-batch, and hollow-fiber or spin-filter perfusion. No single production format is inherently superior; that determination depends on many manufacturing capabilities, requirements, and goals. New cell lines, concerns about product quality and safety, emerging biosimilars, worldwide demand for vaccines, and cellular medicine drive new innovative solutions in bioproduction.

<span class="mw-page-title-main">Edward A. Bayer</span>

Edward A. Bayer is an American-Israeli scientist.

Host cell proteins (HCPs) are process-related protein impurities that are produced by the host organism during biotherapeutic manufacturing and production. During the purification process, a majority of produced HCPs are removed from the final product. However, residual HCPs still remain in the final distributed pharmaceutical drug. Examples of HCPs that may remain in the desired pharmaceutical product include: monoclonal antibodies (mAbs), antibody-drug-conjugates (ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuticals.

References

Official website

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.